Trichotillomania and Excoriation Disorder: Body-Focused Repetitive Behaviors — Neurobiological Mechanisms, Diagnosis, and Evidence-Based Treatment

Trichotillomania (hair-pulling disorder) and excoriation disorder (skin-picking disorder) are the two primary conditions classified under body-focused repetitive behaviors (BFRBs) within the DSM-5-TR chapter on Obsessive-Compulsive and Related Disorders. These conditions are characterized by recurrent, often irresistible urges to pull one's hair or pick at one's skin, resulting in tissue damage, significant distress, and functional impairment. Despite their prevalence and considerable impact on quality of life, BFRBs remain underdiagnosed, undertreated, and underfunded relative to other psychiatric conditions of comparable severity.

The reclassification of these disorders from impulse control disorders (in DSM-IV) to the OCD-related spectrum (in DSM-5 and DSM-5-TR) reflects a growing understanding of shared neurobiological substrates — particularly fronto-striatal circuit dysfunction, imbalances in habit and reward processing, and overlapping genetic vulnerability with OCD. However, BFRBs are not simply variants of OCD. They differ in important ways: the behaviors are often ego-syntonic rather than ego-dystonic, they frequently involve pleasurable or soothing sensory components, and they respond to different treatment approaches than classic obsessive-compulsive disorder.

This article provides an in-depth clinical review of both trichotillomania (TTM) and excoriation disorder (ED), examining their epidemiology, neurobiology, diagnostic assessment, comorbidity patterns, evidence-based treatments, prognostic factors, and current research frontiers. The goal is to equip clinicians and advanced learners with the mechanistic and practical knowledge necessary to recognize and effectively manage these often-overlooked conditions.

Trichotillomania has a lifetime prevalence estimated at 1–2% of the general population, though some surveys suggest rates as high as 3.5% when subthreshold pulling is included. The DSM-5-TR cites a 12-month prevalence of approximately 1–2%. The gender ratio in clinical samples is heavily female-skewed, approximately 9:1 to 10:1 (female to male), though community samples show a more balanced ratio (~3:1), suggesting significant underreporting and treatment-seeking bias in males. Mean age of onset is typically 10–13 years, frequently coinciding with or shortly following puberty, though a separate early-childhood onset subtype (ages 2–6) exists that often remits spontaneously and may represent a developmentally benign habit.

Excoriation disorder has a lifetime prevalence estimated at 1.4–5.4% in community samples, with the DSM-5-TR citing approximately 1.4% for the general population. The female-to-male ratio is approximately 3:1 in clinical samples. Onset is typically in adolescence, often triggered by a dermatological condition (e.g., acne), though it can begin at any age. A significant proportion of individuals with excoriation disorder report onset in adulthood, sometimes precipitated by stressful life events.

The natural history of both conditions tends toward chronicity. Without treatment, TTM follows a waxing-and-waning course, with periods of relative remission followed by exacerbations, often stress-related. Longitudinal data suggest that only about 14–20% of individuals with TTM experience spontaneous, sustained remission. Excoriation disorder follows a similarly chronic trajectory. Both conditions are associated with significant impairment: a survey by the TLC Foundation for BFRBs found that over 60% of individuals with TTM reported avoiding social situations due to shame, and approximately 38% had never disclosed their behavior to a healthcare provider.

Medical complications are clinically significant. In TTM, the ingestion of pulled hair (trichophagia) occurs in approximately 5–20% of cases and can lead to trichobezoars (hair masses in the gastrointestinal tract), which may require surgical removal in severe cases — the so-called Rapunzel syndrome. In excoriation disorder, complications include scarring, infections (including septicemia in extreme cases), and tissue damage requiring dermatological or surgical intervention.

DSM-5-TR Diagnostic Criteria

Trichotillomania (Hair-Pulling Disorder) — DSM-5-TR 312.39 / ICD-11 6B25.0:

• A. Recurrent pulling out of one's hair, resulting in hair loss.
• B. Repeated attempts to decrease or stop hair pulling.
• C. The hair pulling causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.
• D. The hair pulling or hair loss is not attributable to another medical condition (e.g., a dermatological condition).
• E. The hair pulling is not better explained by the symptoms of another mental disorder (e.g., attempts to improve a perceived defect in appearance in body dysmorphic disorder).

Excoriation (Skin-Picking) Disorder — DSM-5-TR 698.4 / ICD-11 6B25.1:

• A. Recurrent skin picking resulting in skin lesions.
• B. Repeated attempts to decrease or stop skin picking.
• C. The skin picking causes clinically significant distress or impairment.
• D. The skin picking is not attributable to the physiological effects of a substance or another medical condition.
• E. The skin picking is not better explained by symptoms of another mental disorder.

Notably, the DSM-5-TR removed the DSM-IV requirement for TTM that the individual experience rising tension before pulling and relief or gratification afterward. This change was critical because research demonstrated that only about 50–60% of individuals with clinically significant hair pulling endorsed this tension-relief cycle, and the old criteria excluded a substantial proportion of impaired individuals.

The Focused vs. Automatic Distinction

A clinically essential assessment dimension involves distinguishing between focused (or intentional) and automatic (or unfocused) pulling/picking. Most individuals engage in both styles, but in varying proportions:

• Automatic pulling/picking occurs outside of awareness — during sedentary activities such as reading, watching television, or driving. The individual may not realize they are pulling until they notice accumulated hair or skin debris. This style is associated with habit-like behavior and engages habitual motor circuits.
• Focused pulling/picking is deliberate and preceded by urges, sensory discomfort (e.g., an "itch" or a feeling that a hair is "not right"), or emotional triggers (anxiety, boredom, frustration). This style is often reinforced by sensory gratification — the tactile sensation of pulling, visual inspection of the root, or the satisfaction of removing a perceived irregularity.

Validated assessment instruments include the Massachusetts General Hospital Hairpulling Scale (MGH-HPS) and the NIMH Trichotillomania Severity Scale (NIMH-TSS) for TTM, and the Skin Picking Scale-Revised (SPS-R) for excoriation disorder. The Milwaukee Inventory for Subtypes of Trichotillomania (MIST) specifically quantifies the focused vs. automatic dimension and is useful for treatment planning, as these subtypes may respond differentially to intervention strategies.

Differential Diagnosis Pitfalls

Several common diagnostic errors deserve attention:

• OCD misdiagnosis: BFRBs are frequently misclassified as OCD. While there is phenomenological overlap (repetitive behaviors, distress), BFRBs typically lack the intrusive, ego-dystonic obsessions that characterize OCD. Hair pulling is more often driven by sensory urges or under-stimulation than by feared consequences or contamination concerns. Furthermore, BFRBs generally do not respond to exposure and response prevention (ERP) as effectively as OCD does.
• Alopecia areata and other dermatological conditions: In TTM, the hair loss pattern is often asymmetric, irregular, and involves hairs of varying length in the affected area ("exclamation point" hairs are absent, unlike alopecia areata). Biopsy can differentiate, showing traumatized follicles and catagen hairs in TTM vs. peribulbar lymphocytic infiltrate in alopecia areata.
• Body dysmorphic disorder (BDD): When pulling/picking is motivated primarily by perceived defects in appearance (e.g., removing hairs perceived as ugly, picking at "imperfections"), BDD should be considered as the primary diagnosis.
• Nonsuicidal self-injury (NSSI): BFRBs are distinct from self-harm driven by emotional regulation of acute distress. NSSI is typically motivated by escape from emotional pain or self-punishment, whereas BFRBs are more often associated with boredom, under-stimulation, or sensory seeking. However, comorbidity is possible.
• Stereotypic movement disorder: In intellectual disability or autism spectrum disorder, repetitive pulling or picking may be better classified as stereotypic movement disorder, particularly when it lacks the cognitive and emotional features (urges, attempts to resist) characteristic of TTM or ED.

Fronto-Striatal Circuitry and Habit Systems

Neuroimaging studies consistently implicate dysfunction in cortico-striato-thalamo-cortical (CSTC) circuits in BFRBs, similar to but distinct from the patterns seen in OCD. Key findings include:

• Increased gray matter density in the left putamen and bilateral cerebellum in TTM, alongside reduced cortical thickness in right inferior frontal gyrus — a region critical for inhibitory control (Chamberlain et al., 2008, 2009).
• Reduced white matter integrity in anterior cingulate, pre-supplementary motor area, and temporal cortex tracts, as demonstrated by diffusion tensor imaging (DTI) studies.
• Functional MRI studies show aberrant activation in the basal ganglia (particularly the caudate and putamen) during response inhibition tasks, suggesting a failure of top-down prefrontal control over automated motor sequences.

The emerging model posits that BFRBs represent a shift from goal-directed to habitual behavioral control — an over-engagement of dorsal striatal "habit" circuits at the expense of ventromedial prefrontal "goal-directed" circuits. This is consistent with the observation that many individuals pull or pick automatically, without conscious awareness.

Neurotransmitter Systems

Multiple neurotransmitter systems have been implicated:

• Serotonin (5-HT): The inconsistent efficacy of SSRIs in BFRBs (in contrast to OCD) suggests that serotonergic dysfunction is not the primary driver, though it likely plays a modulatory role. Some evidence points to altered 5-HT2A receptor binding.
• Dopamine: Given the involvement of striatal habit circuits, dopaminergic signaling is centrally implicated. The partial efficacy of atypical antipsychotics (D2 antagonists) and the worsening of BFRBs with stimulant medications provide indirect pharmacological evidence. The SAPAP3 knockout mouse — which exhibits compulsive grooming resulting in skin lesions — shows excess glutamatergic and dopaminergic transmission in the striatum and is considered a face-valid animal model of excoriation disorder.
• Glutamate: This is perhaps the most actively investigated system. The efficacy of N-acetylcysteine (NAC), a glutamate modulator that restores extrasynaptic glutamate levels in the nucleus accumbens via the cystine-glutamate antiporter, provides pharmacological evidence for glutamatergic dysregulation. The landmark Grant et al. (2009) trial of NAC in TTM showed significant benefit over placebo.
• Opioid system: The pleasurable or soothing qualities of pulling/picking suggest endogenous opioid involvement. The efficacy of naltrexone (a mu-opioid antagonist) in some patients, particularly those with significant urge-driven, gratification-seeking pulling, supports this hypothesis.
• GABA: GABAergic dysfunction in the striatum and cortex is hypothesized to contribute to deficits in inhibitory control.

Genetic and Molecular Factors

BFRBs demonstrate moderate heritability. Twin studies estimate the heritability of TTM at approximately 40–80%. First-degree relatives of individuals with TTM have a significantly elevated risk (~5-fold) of having a BFRB themselves. Candidate gene studies and genome-wide association studies (GWAS) have implicated:

• SAPAP3 (DLGAP3): A postsynaptic density scaffolding protein at glutamatergic synapses in the striatum. Rare variants in this gene have been associated with both TTM and OCD, and the SAPAP3 knockout mouse is a primary animal model.
• SLITRK1: A neuronal transmembrane protein involved in neurite outgrowth, also implicated in Tourette syndrome.
• HoxB8: Knockout mice exhibit excessive grooming behavior; this gene is expressed in OCD-related circuits.
• SLC6A4 (serotonin transporter): Polymorphisms have been inconsistently associated with TTM.

The genetic architecture likely involves a polygenic model with many common variants of small effect, plus rare variants of larger effect in genes related to glutamatergic synaptic function and cortico-striatal circuit development.

Both TTM and excoriation disorder are characterized by high rates of psychiatric comorbidity, which complicate treatment and worsen prognosis:

• Major depressive disorder (MDD): Present in approximately 39–65% of individuals with TTM and 26–48% of those with excoriation disorder. Depression may be both a predisposing factor (emotional dysregulation increasing pulling/picking) and a consequence (shame, isolation, functional impairment).
• Generalized anxiety disorder (GAD) and other anxiety disorders: Comorbid anxiety disorders are present in approximately 27–57% of TTM cases. Anxiety often serves as a proximal trigger for focused pulling/picking episodes.
• OCD: Co-occurs in approximately 13–27% of TTM cases — significantly higher than the ~2–3% population prevalence, supporting shared genetic and neurobiological vulnerability. When OCD and TTM co-occur, treatment planning must address both conditions, as ERP for OCD does not adequately address the BFRB.
• Other BFRBs: There is substantial within-category comorbidity. Approximately 38% of individuals with TTM also engage in pathological skin picking, nail biting, or cheek chewing. This clustering supports the concept of a shared BFRB diathesis.
• ADHD: Elevated rates of ADHD (approximately 12–16%) in TTM populations are notable and may reflect shared deficits in executive function and inhibitory control. The automatic pulling subtype is particularly associated with attentional difficulties.
• Tic disorders and Tourette syndrome: TTM shows a significant association with tic disorders (approximately 6–12% comorbidity), and some researchers have proposed that TTM may share more phenomenological and neurobiological kinship with tic disorders than with OCD — a "tic-like" model of hair pulling as a complex motor sequence driven by premonitory urges.
• Eating disorders: Comorbidity with eating disorders ranges from 7–20%, potentially reflecting shared impulsivity and body-focused distress dimensions.
• Substance use disorders: Present in approximately 15–19% of TTM cases, often involving alcohol.

Clinically, comorbidity is the rule, not the exception. The presence of comorbid MDD is associated with poorer treatment response to habit reversal training, and comorbid ADHD may undermine behavioral interventions that require sustained self-monitoring. Treatment plans for BFRBs should routinely assess and address comorbid conditions.

Habit Reversal Training (HRT)

Habit reversal training, developed by Azrin and Nunn (1973), is the most extensively studied and best-supported psychosocial treatment for BFRBs. HRT consists of three core components:

1. Awareness training: The patient learns to identify the pulling/picking behavior in real time, recognizing precursor urges, sensory triggers, high-risk situations, and the chain of events leading to an episode.
2. Competing response training: The patient practices a physically incompatible behavior (e.g., clenching fists, gripping an object, pressing hands against thighs) for 1–3 minutes each time an urge to pull/pick arises or the behavior is detected.
3. Social support: A designated support person provides praise for competing response use and gentle prompts when pulling/picking is observed.

The evidence base for HRT in TTM is robust. A meta-analysis by Bloch et al. (2007) of behavioral treatments for TTM found a large pooled effect size (Cohen's d = 1.14) for HRT compared to control conditions. The landmark randomized controlled trial by Woods et al. (2006) comparing HRT to supportive therapy found that 66% of HRT recipients achieved a clinically significant response at post-treatment, vs. 8% for supportive therapy. Response was defined as ≥35% reduction on the MGH-HPS plus a CGI-Improvement rating of "much improved" or "very much improved."

For excoriation disorder, Schuck et al. (2011) and other trials have demonstrated comparable efficacy of HRT-based protocols, with effect sizes in the medium-to-large range (d = 0.7–1.2).

Comprehensive Behavioral Treatment (ComB)

The Comprehensive Behavioral Treatment model (ComB), developed by Mansueto et al. (1997), extends HRT by addressing the full range of modalities that trigger and maintain pulling/picking — cognitive, affective, motoric, sensory, and environmental (captured by the acronym SCAMP: Sensory, Cognitive, Affective, Motor, Place). ComB involves a functional assessment of the individual's pulling/picking pattern and selects targeted interventions for each contributing modality. For a patient whose pulling is triggered by coarse-textured hairs (sensory), occurs while studying alone (environmental), and is maintained by tension relief (affective), ComB would address all three domains. Open trials suggest comparable efficacy to standard HRT, with the advantage of greater individualization.

ACT-Enhanced Behavior Therapy (AEBT)

The integration of Acceptance and Commitment Therapy (ACT) principles with HRT represents a major treatment advance. ACT-enhanced behavior therapy (AEBT), developed and tested by Woods and Twohig, adds components of psychological flexibility, acceptance of urges without acting on them, cognitive defusion from pulling/picking-related thoughts, and values-based motivation. The rationale is that attempting to suppress urges paradoxically increases their intensity, while acceptance-based strategies reduce the struggle with urges and enhance willingness to use competing responses.

The pivotal RCT by Woods et al. (2006) tested a combined HRT/ACT protocol. Subsequent studies have shown that ACT-enhanced HRT produces response rates of 56–77% at post-treatment, with some studies showing maintained gains at 3- and 6-month follow-up in approximately 60–70% of initial responders. This is a crucial finding, because relapse is the central challenge in BFRB treatment.

Telehealth and Digital Interventions

Given the scarcity of clinicians trained in BFRB-specific behavioral interventions, telehealth delivery of HRT and ComB has been tested. The TLC Foundation-funded trial by Diefenbach et al. (2020) demonstrated that telehealth-delivered HRT was non-inferior to in-person treatment for TTM, expanding access significantly. Digital therapeutic platforms and mobile apps (e.g., HabitAware's Keen bracelet for awareness training) represent emerging adjuncts, though RCT data remain limited.

SSRIs: Limited and Inconsistent Efficacy

Despite their status as first-line treatments for OCD, SSRIs have shown inconsistent and generally modest efficacy for BFRBs. This is one of the key clinical distinctions between BFRBs and OCD. Early open-label studies suggested benefit, but controlled trials have been largely disappointing:

• A Cochrane meta-analysis (Hoffman et al., 2021) of pharmacotherapy for TTM found no statistically significant advantage of SSRIs over placebo across pooled trials, though individual studies showed mixed results.
• Fluoxetine, the most-studied SSRI for TTM, showed initial promise in a small crossover trial by Christenson et al. (1991) but failed to separate from placebo in a subsequent larger RCT.
• For excoriation disorder, SSRI evidence is even more limited. Open-label data suggest some benefit, particularly when comorbid depression or anxiety is present, but no adequately powered RCT has demonstrated robust efficacy.

SSRIs may be useful as adjuncts for treating comorbid depression and anxiety, which can indirectly reduce pulling/picking by lowering emotional triggers. However, they should not be considered primary treatments for the BFRB itself.

N-Acetylcysteine (NAC)

The Grant, Odlaug, and Kim (2009) randomized, double-blind, placebo-controlled trial of NAC at 1200–2400 mg/day in 50 adults with TTM is a landmark study. At 12 weeks, 56% of NAC-treated patients were classified as "much improved" or "very much improved" on the CGI, compared to 16% on placebo — a clinically meaningful difference. The estimated NNT was approximately 2.5, an unusually favorable number. NAC is thought to act by restoring glutamate homeostasis in the nucleus accumbens via the cystine-glutamate antiporter (system Xc-), thereby modulating cortico-striatal excitatory transmission.

However, subsequent replication efforts have produced mixed results. A pediatric RCT by Grant et al. (2016) in adolescents with TTM failed to show significant benefit over placebo, raising questions about age-dependent efficacy. For excoriation disorder, an RCT by Grant et al. (2016) showed benefit of NAC 1200–3000 mg/day. NAC's favorable side-effect profile (primarily GI disturbance) and low cost make it a reasonable first-line pharmacological option, particularly in adults, despite the incomplete replication data.

Clomipramine

Clomipramine, a tricyclic antidepressant with potent serotonin and norepinephrine reuptake inhibition, showed superiority over desipramine in a small but well-designed crossover trial by Swedo et al. (1989) — the first placebo-controlled medication trial in TTM. Response rates were approximately 60% for clomipramine vs. 28% for desipramine. However, clomipramine's anticholinergic side effects, weight gain, cardiac conduction risks, and lethality in overdose limit its clinical use. It is generally reserved for treatment-resistant cases.

Glutamate Modulators: Beyond NAC

Given the glutamatergic hypothesis, other glutamate-modulating agents have been investigated. Inositol showed negative results. Memantine (an NMDA receptor antagonist) has shown promise in small open-label studies. Riluzole, a glutamate release inhibitor FDA-approved for ALS, has shown preliminary benefit in case series but lacks RCT data for BFRBs.

Opioid Antagonists: Naltrexone

Naltrexone (50–150 mg/day) has been studied based on the hypothesis that endogenous opioid release reinforces the pleasurable aspects of pulling/picking. A small RCT by Grant et al. (2014) showed benefit in a subgroup of TTM patients with higher urge intensity, but overall results were not statistically significant. Naltrexone may be most useful for individuals with prominent focused, urge-driven pulling accompanied by gratification, suggesting that the opioid system may be differentially involved across subtypes.

Atypical Antipsychotics

Olanzapine showed efficacy in a small RCT by Van Ameringen et al. (2010), with 85% response in the olanzapine group vs. 17% placebo (n = 25). The effect is hypothesized to relate to dopaminergic and serotonergic modulation in the striatum. However, metabolic side effects (weight gain, dyslipidemia, glucose dysregulation) limit long-term utility. Aripiprazole has shown promise in case reports but lacks controlled data.

Comparative Effectiveness

Head-to-head comparisons are limited, but the available evidence suggests the following hierarchy:

• Behavioral therapy (HRT/ACT-enhanced) is more effective than pharmacotherapy for both TTM and excoriation disorder, with larger effect sizes (d ≈ 1.0–1.4 for HRT vs. d ≈ 0.3–0.8 for medications).
• The combination of HRT + medication has not been clearly shown to be superior to HRT alone in available trials, though the research is limited and likely underpowered.
• Among medications, clomipramine and NAC have the strongest evidence for TTM, while SSRIs have the weakest.
• For excoriation disorder, NAC and SSRIs have the most data, though the evidence base is considerably thinner than for TTM.

Understanding who responds to treatment — and who does not — is essential for clinical decision-making. Research has identified several prognostic factors:

Positive Prognostic Indicators

• Predominantly automatic pulling/picking: Individuals whose behavior is primarily automatic (rather than focused) tend to respond better to awareness training components of HRT, which directly target the core deficit (lack of behavioral awareness).
• Higher treatment motivation and self-monitoring compliance: Consistent with behavioral intervention research generally, engagement with homework and self-monitoring predicts better outcomes.
• Absence of severe comorbid depression: Moderate-to-severe MDD reduces engagement with and response to behavioral interventions. Treating depression first (or concurrently) improves BFRB treatment outcomes.
• Shorter duration of illness: Earlier intervention is associated with better response, possibly reflecting less entrenched habit circuits.
• Single pulling/picking site: Involvement of multiple sites is associated with greater severity and poorer outcomes.

Negative Prognostic Indicators

• Predominantly focused pulling/picking with strong urge-driven and sensory gratification components: This subtype is more difficult to treat because the behavior is directly reinforced by pleasurable sensory feedback, creating a stronger reinforcement loop.
• Comorbid ADHD: Attentional deficits impair the self-monitoring that is central to HRT. Treating ADHD pharmacologically may improve behavioral therapy response.
• Dissociative pulling: A subset of patients pull/pick in trance-like dissociative states, making awareness training particularly challenging.
• Social isolation and lack of social support: The social support component of HRT requires a willing, nonjudgmental support person; its absence weakens the intervention.
• Childhood onset with continuous course into adulthood: This pattern suggests deeply ingrained habitual behavior with greater neurobiological entrenchment.

Relapse and Long-Term Outcomes

Relapse is the most significant clinical challenge in BFRB treatment. Even among treatment responders, relapse rates of 30–60% at 3–6 months post-treatment are commonly reported. The Keijsers et al. (2006) follow-up study of HRT for TTM found that approximately only 30–40% of post-treatment responders maintained full gains at 2-year follow-up. Booster sessions, ongoing self-monitoring, and relapse prevention planning are essential. The integration of ACT components appears to reduce relapse rates by fostering values-based motivation that persists beyond the treatment window.

Pediatric TTM deserves special consideration. In young children (ages 2–6), hair pulling is common and often represents a developmentally benign habit that resolves without intervention, similar to thumb sucking. Formal TTM diagnosis should be applied cautiously before age 6–7. When treatment is warranted in older children and adolescents, age-adapted HRT with parent involvement is the recommended first-line approach.

The pediatric treatment evidence base was strengthened by the Franklin et al. (2011) RCT comparing behavior therapy (HRT-based) to minimal attention control in children and adolescents with TTM. Behavior therapy produced a response rate of approximately 70%, with large effect sizes. Pharmacotherapy evidence in pediatric populations is weaker: the failed NAC trial in adolescents (Grant et al., 2016) and a lack of well-controlled SSRI trials in youth underscore that behavioral intervention is the clear first-line treatment for pediatric BFRBs.

In adults with intellectual disability or autism spectrum disorder, repetitive hair pulling or skin picking may meet criteria for stereotypic movement disorder with self-injurious behavior rather than TTM or excoriation disorder, depending on whether the cognitive features (urges, attempts to resist, distress about the behavior) are present. Behavioral approaches emphasizing environmental modification and differential reinforcement may be more appropriate than standard HRT in this population.

Given the fronto-striatal circuitry implicated in BFRBs, neurostimulation approaches are being explored:

• Transcranial magnetic stimulation (TMS): Preliminary data suggest that repetitive TMS (rTMS) targeting the supplementary motor area (SMA) or right dorsolateral prefrontal cortex (dlPFC) may reduce pulling urges and behavior in TTM. A small sham-controlled study by Liang et al. (2021) showed promising results, but replication in larger samples is needed.
• Transcranial direct current stimulation (tDCS): Anodal stimulation of the right dlPFC to enhance inhibitory control is under investigation. Results are preliminary and inconsistent.
• Deep brain stimulation (DBS): Given success in treatment-refractory OCD (targeting the ventral capsule/ventral striatum or subthalamic nucleus), DBS for severe, refractory BFRBs has been discussed in the theoretical literature, but no systematic trials have been conducted. The risk-benefit ratio does not currently support DBS for BFRBs outside of extreme, treatment-refractory cases.

Other emerging interventions include:

• Cannabinoid-based treatments: The endocannabinoid system's role in habit learning and reward processing has generated interest in cannabinoid modulation, particularly dronabinol (synthetic THC). A pilot study by Grant et al. (2011) showed significant reduction in TTM symptoms with dronabinol, but the evidence remains preliminary.
• Psilocybin and psychedelic-assisted therapy: Emerging case reports describe BFRB improvement following psilocybin-assisted therapy, potentially through serotonergic modulation and disruption of rigid behavioral patterns. This is highly speculative and no controlled data exist.
• Device-based awareness monitoring: Wearable devices (e.g., the Keen2 smart bracelet by HabitAware) use gesture detection to provide vibratory alerts when pulling/picking motions are detected. These serve as technological augmentation of awareness training and have shown promising usability and satisfaction data, though rigorous RCT evidence of efficacy is lacking.

Despite significant progress, the BFRB field faces several critical limitations and open questions:

Key Limitations

• Small sample sizes: Most RCTs in BFRBs have enrolled 20–60 participants. This limits statistical power and the ability to detect moderators of treatment response. The field has no equivalent of OCD's large-scale trials (e.g., the Pediatric OCD Treatment Study [POTS] with n = 112).
• Limited long-term follow-up data: Few studies extend beyond 6 months post-treatment. The high relapse rate makes long-term data essential for understanding the true clinical value of interventions.
• Sparse data on excoriation disorder: The majority of BFRB research focuses on TTM; excoriation disorder remains under-studied, with fewer RCTs and no FDA-approved treatments.
• Lack of biomarkers: There are no validated biological markers for diagnosis, treatment selection, or prognosis. Treatment remains empirically guided rather than precision-targeted.
• Workforce limitations: Fewer than 1 in 5 mental health professionals report familiarity with evidence-based BFRB treatments. The TLC Foundation estimates that the average individual with TTM sees 3–5 clinicians before receiving appropriate treatment.

Active Research Frontiers

• Computational psychiatry approaches: Applying reinforcement learning models to quantify habit strength and the balance between goal-directed and habitual behavioral control in BFRBs. These models may identify computational biomarkers that predict treatment response.
• Subtyping and precision treatment: The focused/automatic distinction is a beginning, but more granular phenotyping — potentially incorporating neuroimaging, genetics, and computational measures — could enable precision treatment matching.
• Mechanisms of relapse: Understanding why gains from HRT erode is critical. Research is examining whether relapse reflects reconsolidation of the original habit memory, extinction of competing responses, or changes in motivational context.
• Combination treatment optimization: Properly powered trials of HRT + pharmacotherapy (NAC, clomipramine) are needed to determine whether combination approaches reduce relapse.
• Genetic research: Larger GWAS studies, currently underway, may identify additional risk loci and clarify the genetic relationship between BFRBs, OCD, and tic disorders.

Based on the current evidence, the following treatment algorithm is recommended:

First-Line Treatment

Habit reversal training (HRT), ideally enhanced with ACT components (AEBT), delivered by a clinician trained in BFRB-specific behavioral interventions. The Comprehensive Behavioral Treatment (ComB) model is an acceptable alternative framework. Treatment should involve 8–12 weekly sessions, with booster sessions and a formal relapse prevention plan. Expected response rate: 56–77%.

Pharmacological Augmentation or Alternative (When Behavioral Therapy Is Insufficient or Unavailable)

• N-acetylcysteine (1200–2400 mg/day) is the recommended first-line pharmacological option for TTM in adults, given its efficacy data, favorable side-effect profile, and low cost.
• Clomipramine (50–250 mg/day) is a second-line option for TTM, particularly when comorbid depression is present, though monitoring for cardiac and anticholinergic side effects is necessary.
• SSRIs are appropriate for treating comorbid depression and anxiety but should not be relied upon as primary BFRB treatments.
• Naltrexone (50–150 mg/day) may be considered for individuals with prominent urge-driven, gratification-seeking pulling.

Treatment-Resistant Cases

For individuals who have not responded to adequate trials of behavioral therapy and pharmacotherapy:

• Consider olanzapine augmentation (with careful metabolic monitoring).
• Reassess for comorbid conditions that may be undermining treatment (untreated ADHD, MDD, substance use).
• Consider intensive or residential behavioral treatment programs.
• Explore neurostimulation (rTMS) as an experimental option in research settings.

Throughout treatment, clinicians should address the shame and secrecy that pervade these conditions. Many patients with BFRBs have never told anyone about their behavior. Normalizing the condition, providing psychoeducation about its neurobiological basis, and connecting patients with support communities (e.g., the TLC Foundation for BFRBs) are essential components of comprehensive care.